SC
CRSP icon

Sculptor Capital’s CRISPR Therapeutics CRSP Stock Holding History

Sculptor Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-76,700
Closed -$4.67M – 240
2019
Q4 		$4.67M Hold
76,700
– – 0.05% 126
2019
Q3 		$3.14M Sell
76,700
-5,600
-7% -$268K 0.03% 156
2019
Q2 		$3.88M Hold
82,300
– – 0.02% 138
2019
Q1 		$2.94M Buy
+82,300
New +$2.85M 0.02% 125

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sculptor Capital's CRSP Position: Q1 2020 in Review

Sculptor Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 76,700 shares — an estimated $4.67M sold.

Sculptor Capital first reported a position in CRSP in Q1 2019 and held it in 4 quarters. The position peaked at $4.67M in Q4 2019. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

  • Sculptor Capital reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Sculptor Capital sold 76,700 CRISPR Therapeutics shares in Q1 2020, an estimated $4.67M.
  • Sculptor Capital first reported a position in CRISPR Therapeutics in Q1 2019 and held it in 4 quarters.
  • Sculptor Capital's CRISPR Therapeutics position peaked at $4.67M in Q4 2019.
  • 257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on Sculptor Capital's 13F filing for Q1 2020, filed 14 May 2020.